miklos pless
机构: Kantonsspital Winterthur
每年引用次数
引用次数
引用: 15,662
H-指数: 48
I10-指数 : 106
出版物: 371
C3-07: Preoperative chemoradiotherapy followed by surgery for stage IIIB non-small cell lung cancer (NSCLC). A multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)
Roger Stupp , Roger Kann , Abderrahim Zouhair , Michael Mayer
Journal of Thoracic Oncology 2 ( 8) S367 -S368
2007
Meta-analysis of toxicity data in thoracic and abdominal malignancies from: Clinical trials in tumor treating fields.
Ignace Vergote , Fernando Rivera , Miklos Pless , Giovanni L. Ceresoli
Journal of Clinical Oncology 37 ( 15_suppl) e14658 -e14658
2019
Gene Profiling of Clinical Routine Biopsies and Prediction of Survival in Non–Small Cell Lung Cancer
Florent Baty , Michaël Facompré , Sergio Kaiser , Martin Schumacher
American Journal of Respiratory and Critical Care Medicine 181 ( 2) 181 -188
46
2010
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Monika Jermann , Rolf A Stahel , Marc Salzberg , Thomas Cerny
Cancer Chemotherapy and Pharmacology 57 ( 4) 533 -539
53
2006
Second-line therapy to improve overall survival in primary refractory non small-cell lung cancer (NSCLC) patients.
Sacha Rothschild , Rebecca Nachbur , Natascha Herzog , Jakob Passweg
Journal of Clinical Oncology 36
2018
A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).
J. Randolph Hecht , Aleix Prat , Miklos Pless , Antonio Cubillo
Journal of Clinical Oncology 36
2
2018
Early safety from a phase 1, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected into liver tumors.
J. Randolph Hecht , Miklos Pless , Antonio Cubillo , Aitana Calvo
Journal of Clinical Oncology 36 438 -438
4
2018
Abstract CT202: Safety of Tumor Treating Fields delivery to the torso: Pooled analysis from TTFields clinical trials
Giovanni Luca Ceresoli , Ignace Vergote , Fernando Rivera , Miklos Pless
Cancer Research 79
2019
Synergy of growth factors during mobilization of peripheral blood precursor cells with recombinant human Flt3-ligand and granulocyte colony-stimulating factor in rabbits
Miklos Pless , Aleksandra Wodnar-Filipowicz , Linde John , Helen Baldomero
Experimental Hematology 27 ( 1) 155 -161
14
1999
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
Yannis Metaxas , Gareth Rivalland , Laetitia A. Mauti , Dirk Klingbiel
Journal of Thoracic Oncology 13 ( 11) 1784 -1791
49
2018
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Michael Mark , , Patrizia Froesch , Eric Innocents Eboulet
Cancer Immunology, Immunotherapy 70 ( 5) 1255 -1262
1
2021
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rafael Rosell , Urania Dafni , Enriqueta Felip , Alessandra Curioni-Fontecedro
The Lancet Respiratory Medicine 5 ( 5) 435 -444
106
2017
Acute Fatal Liver Toxicity under Erlotinib.
Sabina Schacher-Kaufmann , Miklos Pless
Case Reports in Oncology 3 ( 2) 182 -188
11
2010
Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.
Miklos Pless , Christian Waldherr , Helmut Maecke , Carlos Buitrago
Lung Cancer 45 ( 3) 365 -371
29
2004
A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer.
Miklos Pless , Cornelia Droege , Roger von Moos , Marc Salzberg
Lung Cancer 81 ( 3) 445 -450
83
2013
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Francesco Zappa , Cornelia Droege , Daniel Betticher , Roger von Moos
Lung Cancer 78 ( 3) 239 -244
36
2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.
Oliver Gautschi , Anne-Marie Dingemans , Susanne Crowe , Solange Peters
Lung Cancer 79 ( 1) 59 -64
25
2013
A translational study of Tumor Treating Fields in non small cell lung cancer
Miklos Pless , Uri Weinberg , Daniel Betticher , Moshe Giladi
Cancer Research 72 ( 8\_Supplement) 4607 -4607
3
2012
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
Adrianus Johannes de Langen , Melissa L Johnson , Julien Mazieres , Anne-Marie C Dingemans
The Lancet 401 ( 10378) 733 -746
2
2023
SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non--small-cell lung cancer—a multicenter single-arm phase II trial
Sacha I Rothschild , Alfred Zippelius , Eric I Eboulet , Spasenija Savic Prince
Journal of clinical oncology 39 ( 26) 2872 -2880
96
2021